News | Quercis Pharma

QUERCIS

ABOUT

TEAM

SCIENCE

HIGHLIGHTS

PUBLICATIONS

EXPANDED ACCESS

NEWS

CONTACT

QUERCIS

News

Recent recognition for Quercis and the clinical milestones ahead.

Recent Updates

Nominated for the 2026 Prix Galien USA Award – Best Startup

Nominated for 2025 Galien Award – Best Startup

Recognized as a Top 10 Drug Discovery & Development Solutions Provider in Europe (Life Sciences Review, 2023)

CEO Thomas Lines featured in The Silicon Review for leadership in global health innovation

Upcoming

Phase III trial for Kinisoquin™ in cancer-associated thrombosis (CAT) ongoing under FDA Special Protocol Agreement; interim data expected Q2 2027

Phase III in Sickle Cell Disease (SCD); steady-state data expected Q4 2026

Phase II trial with Administration for Strategic Preparedness and Response (ASPR)

QUERCIS

Heal the world

™

Kinisoquin™ is an investigational therapy in clinical development. It has not been approved for use by any regulatory authority.

QUERCIS

Heal the world

™

Kinisoquin™ is an investigational therapy in clinical development. It has not been approved for use by any regulatory authority.

QUERCIS

Heal the world

™

Kinisoquin™ is an investigational therapy in clinical development. It has not been approved for use by any regulatory authority.